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Abstract
Background: Biologic therapy has changed the prognosis of patients with juvenile idiopathic arthritis (JIA). The aim
of this study was to examine the pattern of use, drug survival, and adverse events of biologics in patients with JIA
during the period from diagnosis to adulthood.
Methods: All patients included in BIOBADASER (Spanish Registry for Adverse Events of Biological Therapy in
Rheumatic Diseases), a multicenter prospective registry, diagnosed with JIA between 2000 and 2015 were analyzed.
Proportions, means, and SDs were used to describe the population. Incidence rates and 95% CIs were calculated to
assess adverse events. Kaplan-Meier analysis was used to compare the drug survival rates.
Results: A total of 469 patients (46.1% women) were included. Their mean age at diagnosis was 9.4 ± 5.3 years.
Their mean age at biologic treatment initiation was 23.9 ± 13.9 years. The pattern of use of biologics during their
pediatric years showed a linear increase from 24% in 2000 to 65% in 2014. Biologic withdrawal for disease remission
was higher in patients who initiated use biologics prior to 16 years of age than in those who were older (25.7% vs
7.9%, p < 0.0001). Serious adverse events had a total incidence rate of 41.4 (35.2–48.7) of 1000 patient-years. Patients
younger than 16 years old showed significantly increased infections (p < 0.001).
Conclusions: Survival and suspension by remission of biologics were higher when these compounds were initiated
in patients with JIA who had not yet reached 16 years of age. The incidence rate of serious adverse events in
pediatric vs adult patients with JIA treated with biologics was similar; however, a significant increase of infection
was observed in patients under 16 years old.
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Background
Juvenile idiopathic arthritis (JIA) comprises a group of dis-
eases of unknown etiology that have in common arthritis
in at least one joint persisting for at least 6 weeks in pa-
tients younger than 16 years of age [1]. JIA is the most fre-
quent chronic rheumatic disease in childhood [2–4] and is
classified into seven categories: systemic, persistent or
extended oligoarthritis, rheumatoid Factor (RF) positive
polyarthritis, RF-negative polyarthritis, enthesitis-related
arthritis, psoriatic arthritis, and undifferentiated arthritis
[1]. When uncontrolled, JIA leads to severe joint damage
and impairment in skeletal maturation [5–7]. Fortunately,
during the last decade, the arrival of biologics has dramat-
ically changed the prognoses for these patients [8, 9]. A
number of well-designed clinical trials, as well as cohort
studies, have demonstrated that biologics are an effective
option for patients with JIA who do not respond to or who
cannot tolerate treatment with synthetic disease-modifying
antirheumatic drugs (DMARDs) [10–12]. Some studies
have shown that the sooner treatment is begun for JIA and
the more aggressive it is, the better the outcomes obtained
[13–16]. The ReACCh-Out cohort studied remission in pa-
tients with JIA in Canada and concluded that the probabil-
ity of attaining remission with contemporary treatments
within 5 years of diagnosis averaged about 50%, except for
children with polyarthritis [17].
JIA is not confined to childhood, and 41% of patients re-
quire medication in their thirties, with some 28% main-
taining high disease activity [18]. The transition period
from pediatric- to adult-focused health care for adoles-
cents with chronic conditions is attracting growing atten-
tion [19]. A recent study assessing the importance of
transition to adult rheumatologic care in young people
with JIA concluded that the maintenance of JIA diagnosis
and DMARD therapy depended on the use of specialized
care services [20]. Nowadays, young people with rheum-
atic diseases have a greater rate of survival, although high
morbidity persists that could be avoided, in part, with
multidisciplinary management [21]. Recently, several pro-
fessional groups and international agencies have attempted
to create consensus recommendations and guidelines try-
ing to improve this situation [22, 23]. Data from the British
Society for Rheumatology Biologics Register shows that
tumor necrosis factor inhibitor (TNFi) therapies are an ef-
fective treatment option for adults with JIA, with a safety
profile similar to that seen in rheumatoid arthritis (RA)
[24]. However, because adults with JIA comprise a hetero-
geneous group of patients whose clinical evolution, need
for, and response to treatments are not well studied,
follow-up and monitoring of these patients are required
[25]. The aim of the present study was to evaluate the pat-
tern of use, the survival, and the safety of biologic agents
in patients with JIA during the period from diagnosis to
adulthood who are included in the BIOBADASER registry.
Methods
Study design
BIOBADASER (Spanish Registry for Adverse Events of Bio-
logical Therapy in Rheumatic Diseases) is a multicenter
prospective observational study monitored annually, the
main objective of which is long-term safety assessments of
patients who undergoing biologic therapies [26, 27]. Estab-
lished in February 2000, BIOBADASER is based on clinical
practice. The quality of the database is ensured by a clear
definition of its aim, an optimized number of variables, and
an easy method of data collection that allows for
consistency checks. Incompleteness and agreement of data
with patient charts are assessed by online monitoring of
the entire included population and by on-site annual audits
of 10% of the patients registered. All detected errors and
inconsistencies are corrected on the basis of results of said
monitoring. The BIOBADASER registry is supported by
the Spanish Medicines Agency, and the clinical studies
were approved by the ethics committee of Hospital Clinic
Barcelona. All patients included in the BIOBADASER
registry, or their legal representatives, signed a written
informed consent prior to inclusion.
Population
For this analysis, we selected all adult patients included in
the database diagnosed with JIA. Owing to the initial
design of the registry (BIOBADASER was not initially
designed as a specific registry for JIA), patients with JIA
were classified into systemic/oligoarthritis/polyarticular
JIA, JIA related to enthesitis, or psoriatic JIA. Patients
were enrolled in the registry when biologic treatment was
initiated, and they were followed prospectively and evalu-
ated if an adverse event (AE) occurred or if a change in
the biologic therapy was decided either owing to an AE or
because of inefficacy. The analysis of this study includes
data from 2000 to December 2015, and only those patients
still under active follow-up at the end of the study period
were included.
Variables
The following data were collected: (1) patient data, includ-
ing gender, date of birth, diagnosis, date of diagnosis, and
comorbidities; (2) data on treatment, including types of bi-
ologics and dates of initiation and discontinuation, reason
for discontinuation, concomitant antirheumatic treatment
and tuberculosis (TB) prophylaxis; and (3) data on AEs,
including date of occurrence, type and classification of AE
according to the Medical Dictionary for Regulatory
Activities [MedDRA]) v13 [28], severity, and outcome.
Statistical analysis
The patients included were described using descriptive
statistics indicated by the type and distribution of vari-
ables. Proportions, means, and SDs or IQRs were used
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to describe our population and the use of treatments. The
incidence rate (IR) per 1000 patient-years with 95% CI
was estimated by group. Results were expressed as IR with
the 95% CI. Survival rates were defined as end of treat-
ment for any reason. IR comparisons between age groups
were obtained by Poisson regression. Log-rank tests were
used to assess the equality of survivor functions across age
groups, monotherapy vs combined therapy, and treatment
groups. All analyses were performed using Stata version
13.1 software (StataCorp, College Station, TX, USA).
Results
A total of 469 patients from the BIOBADASER registry,
46.1% of them women (n = 216), were classified as
systemic/oligoarthritis/polyarticular JIA (70.5%), JIA related
to enthesitis (25%), and psoriatic JIA (4.5%). The mean age
was 34.5 years (SD = 15.3). The mean age at diagnosis was
9.4 years (SD = 5.3), and the mean evolution years was 24.1
(SD = 14.1). Uveitis was recorded in 12.6% of patients (50%
of them antinuclear antibody [ANA]-positive). Overall, the
ANA test result was positive in 30.2% of patients with
systemic/oligoarthritis/polyarticular JIA, 14.3% of patients
with psoriatic JIA, and 6.8% of patients with enthesitis.
HLA-B27 was determined in 42.9% of patients, with 22%
testing positive (59.8% in enthesitis-related arthritis, 23.8%
in psoriatic arthritis, and 8.5% in systemic/oligoarthritis/
polyarticular JIA). The mean age at the beginning of
biologic treatment was 23.9 years (SD = 13.9), and the
mean number of years that patients were treated with these
compounds was 9.6 (SD = 3.8). Table 1 shows the baseline
characteristics of patients included in this analysis.
Table 2 shows the biologics and concomitant treat-
ments. The most frequently used biologics as first-line
treatments were etanercept (43.5%), infliximab (30.5%),
and adalimumab (19%). Almost half of the patients in-
cluded in the registry (42.4%) were receiving monotherapy
with biologics, and corticoids were used in 32.3% of
patients with JIA. With respect to the pattern of use, Fig. 1
shows the annual percentage of patients diagnosed of JIA
from 2000 to 2015 whose treatment with biologics began
at age 16 years or younger (n = 137). In 2000, 25% of
patients received the first biologic at a pediatric age, with
this percentage increasing linearly until reaching 65% in
2015. The mean age of patients who started biologic
treatment before 16 years of age was 8.06 years (SD = 4.3).
Table 3 shows the type of biologic used in the initial
treatment of patients younger vs older than 16 years old.
Etanercept was the most frequently prescribed drug as a
first-line treatment in patients under 16 years old (59.1%),
whereas infliximab was the most often biologic used in
those aged 16 years or older (40.4%). Maintaining this div-
ision, the reasons for suspension in both groups of ages
were inefficiency (37.1% and 37.4%, respectively), followed
by adverse effects (28.6% and 28%, respectively). The
suspension rate due to disease remission was higher in
patients who initiated biologic treatment before 16 years
old (25.7%) than in those who began it at 16 years old or
later (7.9%; p < 0.0001). A total of 266 (56.7%) patients
received only one biologic, and 7.5% were treated with five
or more such compounds.
With respect to survival rates by age groups, retention
of the first biologic was higher when it was started
before 16 years of age (p = 0.02) (Fig. 2a). However, when
survival rates were analyzed in patients who had
received biologics as monotherapy or in combination, no
significant differences were observed in terms of biologic
retention (p = 0.52) (Fig. 2b). Regarding the therapeutic
target, a nonsignificant tendency toward a better reten-
tion of TNFi compounds with respect to non-TNFi was
observed (p = 0.06) (Fig. 2c) when they were analyzed as
a first- or second-line treatment.
Table 4 shows that the most frequent AEs were infec-
tions, gastrointestinal disorders, skin and subcutaneous
tissue disorders, and site-of-administration reactions. Re-
garding serious AEs, no differences were observed if the
biologic therapy was initiated before age 16 years vs
Table 1 Baseline characteristics of patients included in the
study
Variable Median (IQR) (Years) No. (%)
Total number of patients 469
Sex, female 216 (46.1)
Agea 32.8 [22.8–43.6]
Age at diagnosis 10.3 [4.4–14.3]
Age at the beginning of biological
treatment, median [IQR]**
22.1 [13.9–32.5]
Years of disease progression 22.5 [12.3–33.9]





- Enthesitis-related arthritis 117 (25)
- Psoriatic arthritis 21 (4.5)
Positive RF 32 (6.8)
ANA-positive 111 (23.7)
HLA-B27-positive:
- Positive 103 (22)
- Negative 98 (20.9)
- Not done 268 (57.1)
Uveitis:
- Without uveitis 410 (87.4)
- Uveitis, ANA-negative 30 (6.4)
- Uveitis, ANA-positive 29 (6.2)
Abbreviations: ANA Antinuclear antibodies, HLA Human leukocyte antigen, JIA
Juvenile idiopathic arthritis, RF Rheumatoid factor
aAge at the end of BIOBADASER phase II (December 2015)
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later. Conversely, the analysis of infections showed a sig-
nificant increase in the IR in patients under 16 years of
age: 253.2 (221.4–289.6) vs 136.0 (122.8–150.6) (p <
0.001). A total of 37.2% of infections occurred during the
first year of treatment (only 4.0% in the first month). Add-
itional file 1: Table S1 shows the frequency of infections
classified by type in patients younger or older than 16 years
old. Only one fatal event (mycoplasma pneumonia in a
patient treated with anakinra) was recorded. The IRs of
total AEs in the three categories in which BIOBADASER
classified patients with JIA were as follows: 424.9 (399.8–
451.7) for systemic/oligoarthritis/polyarticular JIA, 262.8
(232–297.9) in cases of enthesitis, and 252.9 (188.8–338.8)
for psoriatic JIA (p < 0.001). Regarding serious AEs, the
Table 2 Biologics as first-line and subsequently, and
concomitant therapy in patients with juvenile idiopathic arthritis
Drug First-line Second-line or later Total
Etanercept 204 (43.5) 119 (25.8) 323 (34.7)
Infliximab 143 (30.5) 58 (12.6) 201 (21.6)
Adalimumab 89 (19.0) 108 (23.4) 197 (21.2)
Anakinra 8 (1.7) 15 (3.3) 23 (2.5)
Rituximab 0 (0.0) 72 (15.6) 72 (7.7)
Abatacept 5 (1.1) 28 (6.1) 33 (3.6)
Tocilizumab 16 (3.4) 40 (8.7) 56 (6.0)
Golimumab 2 (0.4) 13 (2.8) 15 (1.6)
Certolizumab 2 (0.4) 5 (1.1) 7 (0.8)
Canakinumab 0 (0.0) 2 (0.4) 2 (0.2)
Ustekinumab 0 (0.0) 1 (0.2) 1 (0.1)
Use of concomitant drugs
- Monotherapy 177 (37.7) 217 (47.1) 394 (42.4)
- Methotrexate 225 (48.0) 184 (39.9) 409 (44.0)
- Glucocorticoids 155 (33.1) 145 (31.5) 300 (32.3)
- Leflunomide 29 (6.2) 26 (5.7) 55 (5.9)
- Sulfasalazine 26 (5.5) 13 (2.8) 39 (4.2)
- Gold salts 1 (0.2) – 1 (0.1)
- Azathioprine 3 (0.6) 5 (1.1) 8 (0.9)
- Hydroxychloroquine 4 (0.9) 5 (1.1) 9 (1.0)
Data are expressed as number of patients (%)
Fig. 1 Dot plot showing the variations in the percentage of patients
with juvenile idiopathic arthritis included in BIOBADASER annually who
received their first biologic before age 16 since years 2000 to 2015
Table 3 Characteristics of patients by age at the beginning of
biologic treatment according to biologic compound, number of
biologic drugs, and reasons for suspension
< 16 Years ≥16 Years p Value
Number of patients 137 (29.2) 332 (70.8)
Age at the beginning of
biological treatment
9.0 [4.2] 30.2 [11.4] < 0.001
Years of disease progression 2.7 [3.1] 19.5 [2.1] < 0.001
Biologic compound
Etanercept 81 (59.1) 123 (37.1) < 0.001
Adalimumab 31 (21.6) 58 (17.5)
Infliximab 9 (6.6) 134 (40.4)
Tocilizumab 8 (5.8) 8 (2.4)
Abatacept – 5 (1.5)
Anakinra 6 (4.4) 2 (0.6)
Certolizumab 2 (1.5) –
Golimumab – 2 (0.6)
Reason for suspension
Inefficacy 26 (37.1) 80 (37.4) < 0.001
Remission 18 (25.7) 17 (7.9)
Adverse event 20 (28.6) 60 (28.0)
Loss of tracking 4 (5.7) 20 (9.4)
Pregnancy or gestational desire – 13 (6.1)
Other reasons 2 (2.9) 22 (10.3)
Unknown – 2 (0.9)
Number of biologic drugs
1 drug 83 (60.6) 183 (55.1) 0.244
> 1 drug 54 (39.4) 149 (44.9)
2 27 (19.7) 67 (20.2)
3 13 (9.5) 38 (11.5)
4 11 (8.0) 12 (3.6)
5 or more 3 (2.2) 32 (9.6)
Data are expressed as mean [SD] or as number of patients (%). Chi-squared
tests were used to compare distributions for categorical variables, and
Student’s t tests were used for numerical variables
Bethencourt Baute et al. Arthritis Research & Therapy  (2018) 20:227 Page 4 of 9
IRs were 44.1 (36.5–53.3), 36 (25.7–50.4), and 33.7 (15.2–
75.1), respectively (p = 0.36). When patients with JIA were
classified on the basis of biologic therapy with TNFi or
non-TNFi, the IRs for total AEs were 345.0 (325.1–366.0)
and 617 (541.7–702.8), respectively (p = 0.009). Regarding
serious AEs, the IRs were 78.8 (54.8–113.4) and 37.1
(30.9–44.4), respectively (p = 0.924).
With respect to opportunistic infections, three cases of
pulmonary TB and one case of disseminated TB were
recorded; these patients had received chemoprophylaxis
with isoniazid, except in one case owing to a negative
Mantoux test result.
Discussion
The most important findings of this work can be
summarized as follows:
1. The use of biologics for the management of JIA dur-
ing the pediatric years has consistently increased during
the last 15 years.
2. In patients with JIA treated with biologics before
16 years of age, both the survival and drug withdrawal
due to disease remission are higher than when these
compounds are started during adulthood.
3. The safety of biologics in JIA is similar when used
before or after 16 years of age in cases of serious AEs;
however, in patients younger than 16 years old, infec-
tions are more frequent.
During the last 15 years, the advent of biologic drugs
has changed the prognosis of and therapeutic approach to
many rheumatic diseases, including JIA. As in adults, early
initiation of biologic therapy in pediatric patients with JIA
is important when control of the disease with conven-
tional DMARDs is not achievable [29–31]. Patients with
active JIA refractory to DMARDs and steroids are
currently treated with TNFi or interleukin-6 antagonists
or T-cell activation inhibitors in order to maintain inactive
disease and the remission of JIA. Biologic drugs are typic-
ally well tolerated by children, and that—combined with
early and aggressive therapy—yields optimal outcomes [9].
In this regard, in our present study, the pattern of biologic
use showed that the annual percentage of patients with
JIA who began treatment with these compounds before
reaching 16 years of age increased almost threefold from
2000 to 2015. The biologics used in our registry of pa-
tients were, in order of frequency: etanercept, infliximab,
and adalimumab. Infliximab was the second most used
biologic in our series, with 30.5% of patients receiving this
compound as the first biologic drug. Similarly, previous
studies have reported the use of infliximab as a first
biologic in patients with JIA ranged between 20.6% and
32% [24, 32]. When differentiating whether the treatment
was started before or after 16 years old, it was found than
93% of patients (n = 134) initiated infliximab in adulthood.
The reason for the significant use of infliximab, a TNFi
Fig. 2 Kaplan-Meier survival curves. a Drug survival estimates by age
(p = 0.02). b Drug survival estimates by monotherapy or combined
therapy (p = 0.52). c Drug survival estimates by non-tumor necrosis
factor inhibitor (non-TNFi) or TNF-i, only considering first and second
lines of treatment (p = 0.06)
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without indication in any category of JIA, in patients with
JIA in adulthood may be due to different factors. These
might be that infliximab and etanercept were the first TNFi
available, and for a period of time they were the only bio-
logic available, to treat DMARD-resistant inflammatory
arthritis, as well as the tendency of many rheumatologists
to reclassify adult JIA as RA [20], where infliximab is
indicated.
The variable course of JIA and the passage from ado-
lescence to adulthood constitutes an important challenge
for the physician. According to a study conducted by the
American College of Rheumatology, 45% of pediatric
rheumatologists are reluctant to treat patients aged
18 years and older, and 28% of adult rheumatologists are
treating patients younger than 17 years old [33]. Various
studies have reported that one-third of patients with JIA
continue to present clinical disease activity into adult-
hood [34–36]. In addition, most patients with JIA who
start biologic therapy during childhood reach adulthood
with little evidence to support the benefits of continuing
these treatments [37–39] or even of their long-term
safety. This scenario implies a greater complexity in
monitoring the safety of those drugs than is currently
acknowledged. Studies based on routine clinical practice,
as presented in this work, allow the assessment of treat-
ment effectiveness and long-term adverse reactions in
daily practice.
In our study, those patients who started treatment with
biologics before the age 16 years presented with a percent-
age of drug suspension, owing to disease remission, greater




< 16 years ≥16 years
Total adverse events 457.6 (414.1–505.7) 346.9 (325.4–369.8) < 0.001 373.2 (353.6–393.8)
Serious adverse events 35.7 (24.9–51.0) 43.2 (36.1–51.8) 0.347 41.4 (35.2–48.7)
Fatal adverse events 1.2 (0.2–8.4) – 0.999 0.3 (0.0–2.0)
By system/organ class
Infections and infestations 253.2 (221.4–289.6) 136.0 (122.8–150.6) < 0.001 163.8 (151–177.6)
Gastrointestinal disorders 30.9 (21.0–45.4) 18.1 (13.7–24.0) 0.028 21.1 (16.9–26.5)
Skin and subcutaneous tissue disorders 17.8 (10.7–29.6) 21.1 (16.2–27.3) 0.797 20.3 (16.1–25.6)
General disorders and administration site conditions 21.4 (13.5–34.0) 20.0 (15.3–26.0) 0.566 20.3 (16.1–25.6)
Eye disorders 23.8 (15.3–36.8) 13.3 (9.6–18.4) 0.037 15.8 (12.1–20.5)
Musculoskeletal and connective tissue disorders 11.9 (6.4–22.1) 11.8 (8.4–16.7) 0.988 11.8 (8.7–16)
Surgical and medical procedures 3.6 (1.2–11.1) 13.7 (9.9–18.9) 0.025 11.3 (8.3–15.4)
Nervous system disorders 10.7 (5.6–20.6) 11.5 (8.1–16.3) 0.857 11.3 (8.3–15.4)
Blood and lymphatic system disorders 10.7 (5.6–20.6) 8.9 (5.9–13.2) 0.631 9.3 (6.6–13.1)
Renal and urinary disorders 3.6 (1.2–11.1) 11.1 (7.7–15.9) 0.061 9.3 (6.6–13.1)
Reproductive system and breast disorders 4.8 (1.8–12.7) 9.6 (6.5–14.1) 0.190 8.5 (5.9–12.1)
Injury, poisoning, and procedural complications 8.3 (4.0–17.5) 8.1 (5.4–12.3) 0.957 8.2 (5.7–11.8)
Respiratory, thoracic, and mediastinal disorders 11.9 (6.4–22.1) 5.9 (3.6–9.6) 0.083 7.3 (5–10.8)
Neoplasms: benign, malignant, and unspecified
(including cysts and polyps)
3.6 (1.2–11.1) 5.9 (3.6–9.6) 0.422 5.4 (3.4–8.4)
Hepatobiliary disorders 2.4 (0.6–9.5) 5.9 (3.6–9.6) 0.225 5.1 (3.2–8.1)
Metabolism and nutrition disorders 1.2 (0.2–8.4) 5.9 (3.6–9.6) 0.120 4.8 (3–7.7)
Pregnancy, puerperium, and perinatal conditions 0.0 5.5 (3.3–9.2) 0.997 4.2 (2.5–7)
Vascular disorders 1.2 (0.2–8.4) 4.8 (2.8–8.3) 0.178 3.9 (2.3–6.7)
Psychiatric disorders 5.9 (2.5–14.3) 3.3 (1.7–6.4) 0.298 3.9 (2.3–6.7)
Ear and labyrinth disorders 2.4 (0.6–9.5) 3.0 (1.5–5.9) 0.783 2.8 (1.5–5.2)
Immune system disorders 2.4 (0.6–9.5) 2.6 (1.2–5.4) 0.916 2.5 (1.3–4.9)
Cardiac disorders 3.6 (1.2–11.1) 1.8 (0.8–4.4) 0.368 2.3 (1.1–4.5)
Endocrine disorders 2.4 (0.6–9.5) 1.5 (0.6–3.9) 0.583 1.7 (0.8–3.8)
Congenital, familial, and genetic disorders 0.0 1.8 (0.8–4.4) 0.403 1.4 (0.6–3.4)
Data represent the incidence (95% CI) × 1000 patients/yr
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than that in those who initiated these compounds at a later
age (25.7% vs 7.9%, respectively). Different European
cohorts have reported that male sex and earlier initiation
of biologic therapy increased the likelihood of halting
treatment owing to the onset of clinical remission [40].
With respect to drug survival, we found a significantly
better retention rate when biologics were started before
age 16 than in adulthood. The gap between diagnosis and
biologic treatment initiation in the group of patients youn-
ger than 16 was 2.7 ± 3.1 years. A previous report [41]
found no differences in the retention rates of the biologic
therapy based on the age of treatment initiation in
patients with JIA. In this study, the median age of patients
who started biologic therapy was 16.2 ± 9.4 years old, with
a gap between initiation of biologic treatment and diagno-
sis of 7.5 ± 4.9 years. This difference in start time of
biologic treatment with respect to diagnosis might explain,
at least in part, the divergent results in retention rates
vis-à-vis age of biologic initiation between the two studies.
In terms of drug survival, we found no differences be-
tween the use of biologics in monotherapy vs in combin-
ation, and when differentiated by age, our results were
similar to those previously reported [42].
The aim of this study was to collect long-term out-
come data on children receiving biologic agents for JIA,
not only to assess drug survival but also to explore the
reasons why biologic therapies had been discontinued.
In our group of patients, inefficacy was the main reason
for biologic therapy discontinuation regardless of age at
drug onset, followed by AE and remission. In this regard,
other series have found dissimilar results. Verazza et al.
[43], in a series of 1038 patients with JIA treated with
etanercept, found that the main cause of treatment dis-
continuation was disease remission, followed by ineffi-
cacy and AEs. Nevertheless, in a cohort of 301 patients
with JIA, the most common reasons for stopping bio-
logic treatment were AEs, with infusion reactions being
the most frequently reported [44]. In a comparative
study of adult and juvenile populations with inflamma-
tory arthritis [42], the same biologic therapy profile as in
our study was observed (infliximab vs etanercept) in
both adults and children. Inefficacy was the most
frequent reason for discontinuation of biologic therapy
in both groups, being neuropsychiatric, gastrointestinal,
and ocular complications, but not infections, as the most
frequents AEs in the juvenile population. Although it
may seem interesting to compare incidences of AEs and
survival curves head-to-head for biologic treatments in
adult patients, this would involve analyzing two different
populations with clearly differentiated baseline patholo-
gies and characteristics.
Regarding the limitations of our study, BIOBADASER
was not specifically designed for JIA, and the categorization
of these patients differs from the most currently used
classification [1]. Because correct classification in categories
is important in terms of therapeutic indications and
prognosis, the new 2016 version of BIOBADASER classifies
patients with JIA as systemic, persistent, or extended
oligoarthritis; RF-positive polyarthritis; RF-negative polyar-
thritis; enthesitis-related arthritis; psoriatic arthritis; and
undifferentiated arthritis [1]. Another limitation of our
study is that we did not compare drugs individually. Never-
theless, our results included a safety comparison between
TNFi and other biologic therapies. With respect to
strengths of BIOBADASER, this registry allows the possibil-
ity of studying safety information in biologic treatments in
a large cohort of patients with JIA followed in routine clin-
ical practice by rheumatologists during a relevant period.
BIOBADASER adds to the limitations of randomized clin-
ical trials, which typically include a relatively low number of
subjects followed for a short period of time, which hampers
the ability of such studies to detect rare events and/or
long-term side effects [45].
Conclusions
In summary, thus far, there are few studies based on
general clinical practice that focus on the safety of bio-
logic treatments in patients with JIA. The prospective re-
cords of these adult patients with JIA treated with
biologic therapy can contribute to improving knowledge
about the behavior of this disease in adulthood. In our
study, survival and suspension by remission of biologics
were higher when these compounds were initiated in pa-
tients with JIA who had not yet reached 16 years of age.
The IR of serious AE in child vs adult patients with JIA
treated with biologics was similar.
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